Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the filing of a prospectus with the SEC for the resale of 115,102,400 Ordinary Shares represented by 287,756 American Depositary Shares (ADSs). The shares are related to series D warrants and placement agent warrants issued in an offering. The selling shareholders, identified in the prospectus, may sell the shares on the market or in private transactions. The ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX.' The last reported closing price of the ADSs was $1.27 on May 2, 2024. The company will not receive any proceeds from the sale of the ADSs by the selling shareholders but may receive proceeds from the exercise of warrants under certain circumstances. The prospectus also details the company's right to issue and sell shares, the appointment of JPMorgan Chase Bank, N.A. as the depositary, and the legal and financial advisors involved in the process.

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the filing of a prospectus with the SEC for the resale of 115,102,400 Ordinary Shares represented by 287,756 American Depositary Shares (ADSs). The shares are related to series D warrants and placement agent warrants issued in an offering. The selling shareholders, identified in the prospectus, may sell the shares on the market or in private transactions. The ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX.' The last reported closing price of the ADSs was $1.27 on May 2, 2024. The company will not receive any proceeds from the sale of the ADSs by the selling shareholders but may receive proceeds from the exercise of warrants under certain circumstances. The prospectus also details the company's right to issue and sell shares, the appointment of JPMorgan Chase Bank, N.A. as the depositary, and the legal and financial advisors involved in the process.